Glioma, Immune Suppression
Conditions
Brief summary
Our study considered the relevant immune and inflammatory indices, such as immunoglobulin kappa light chain, TNF, and CD4+ Helper T lymphocyte% in a multi-institutional study with a large patient cohort (n=1282) from the east, northeast, and southeast of China. Our study shed light on the association of peripheral immune system status with prognosis, tumor grade, and subtype of glioma, which can potentially benefit future diagnostic and prognostic processes of glioma given its noninvasive nature. Moreover, the preoperative inflammatory status can be leveraged for timely interventions to reverse the immunosuppressive status of cancer patients and enhance anti-tumour immunity of glioma.
Interventions
OTHERDetection of Immune and Inflammatory Indices in Peripheral Blood
We detected immune and inflammatory indices in peripheral blood at each patient's at first hospitalizatin from October 13th, 2006, to April 6th, 2022.
Sponsors
Sun Yat-sen University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* glioma grading and classification histologically verified in a resection or biopsy specimen according to 2016 WHO criteria; * age \> 18 years; * primary malignant glioma; * the duration of follow-up \> 3 months; * available data of lymphocyte subsets, cytokines, immune proteins and immune complements measured at the patient's first hospitalization. Exculsion Criteria: * current infectious disease, hyperpyrexia, hematological disease, diabetes mellitus, serious heart disease, hypertension, metabolic syndrome, severe renal or hepatic dysfunction, other cancer, autoimmune disease, inflammatory disease, or medication usage related to an inflammatory condition; * prior cancer-specific pretreatment, such as chemotherapy or radiotherapy;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| all-cause mortality | 16 years | For this study, the endpoint was all-cause mortality. Time zero was set at the time of resection of the primary tumor. |
Countries
China
Contacts
Primary ContactSheng Zhong, M.D.
Outcome results
None listed